HBcAg (HBV) (18 - 27)

HBcAg (HBV) (18 - 27) is a synthetic hepatitis B virus-derived antigenic peptide. HBV-derived synthetic peptides from core, surface, envelope, polymerase, and other viral proteins are used to characterize virus-specific cellular immunity. Published studies have mapped multiple HLA-restricted cytotoxic T-cell epitopes using synthetic HBV peptides and demonstrated sequence-specific peptide recognition by CD8-positive T cells. HLA restriction, immunodominance, and functional response vary with the exact residue range and sequence.

• HBV-specific CTL assays
• HLA peptide-binding studies
• viral epitope mapping
• T-cell stimulation controls
• sequence-dependent immune-response studies

For antigenic or viral peptides, HLA restriction, cellular response, and immunological activity should not be inferred solely from the source protein name; the exact sequence, residue numbering, strain or genotype, and experimental system should be considered. For labeled or otherwise modified variants, the modification may also affect binding or assay behavior.

1. HLA-A2-restricted cytotoxic T lymphocyte responses to hepatitis B surface antigen-derived synthetic peptides
2. The cytotoxic T lymphocyte response to multiple hepatitis B virus epitopes